ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives European Commission Marketing Authorization for HIV-1 Infection in Adults and Adolescents

 ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives European Commission Marketing Authorization for HIV-1 Infection in Adults and Adolescents

ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives European Commission Marketing Authorization for HIV-1 Infection in Adults and Adolescents

Shots:

  • The marketing authorization is based on GEMINI 1 & 2 studies result assessing Dovato vs dolutegravir + tenofovir disoproxil fumarate/emtricitabine in 1400+ patients with HIV-1 infection for 48wks.
  • The GEMINI 1 & 2 studies result demonstrated that two drug regimen showed non-inferior efficacy based on plasma HIV-1 RNA <50 copies/ml compared three-drug regimen in treatment-naive HIV-1 infected patient
  • Dovato (DTG 50 mg/3TC 300 mg) is an oral combination therapy and has received the US FDA’s approval in Apr’2019 for HIV-1 infection prior not treated with ARV with no resistance to DTG or 3TC

Click here to read full press release/ article | Ref: GSK | Image: PInterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post